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one-third of the world0s population. Eighteen new 8-substituted berberine derivatives were
synthesized and evaluated for their anti-mycobacterial activities againstMycobacterium tuberculosis
(M. tuberculosis) strain H37Rv. Among these compounds, compound 6i was the most effective
antitubercular agent with an MIC of 1.0 mg/mL. Most importantly, compound 6i also exhibited a
potent effect against clinically isolated rifampicin- and isoniazid-resistant M. tuberculosis strains,
suggesting a different mode of action from the current drugs. Therefore, it shows potential for the
development of new anti-TB agents.
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Tuberculosis (TB), emergence of multidrug-resistance TB
(MDR-TB), and extensively drug-resistance TB (XDR-
TB) are the major causes of death from infectious diseases
worldwide. It is anticipated that there will be about 9.8
million new TB cases this year, more than in any other
year in history1,2. Five percent of all TB cases are now
estimated to be MDR-TB, which is resistant to at least
rifampin (RIF) and isoniazid (INH), the two most important
ﬁrst-line drugs used currently in clinic3,4. The overall incidence
of TB in HIV-positive patients is 50 times that of the rate for
HIV-negative individuals5–7. The difﬁculty in managing TB is
the prolonged treatment duration, the emergence of drug
resistance and co-infection with HIV/AIDS. However, no
new chemical scaffold for the treatment of this disease has
been introduced in the past 40 years8,9 and there is an urgent
need to discover new classes of molecules without cross-
resistance with current anti-mycobacterial drugs9.
In the search for novel-scaffold of anti-mycobacterial
agents, berberine (1) derivative libraries constructed in our
laboratory were screened against drug-susceptible Myco-
bacterium tuberculosis (M. tuberculosis) strain H37Rv, with
RIF and INH as positive drugs10–12. The primary structure-
activity relationship (SAR) analysis indicated that the 8-
substituted dihydropseudoberberine (2) and dihydropalma-
tine (3) derivatives showed moderate antibacterial activity
against M. tuberculosis (Fig. 1). Based on these preliminary
results, a series of new 8-substituted 2 and 3 derivatives was
designed, prepared, and evaluated for their anti-mycobacterial
effect against the drug-susceptible H37RV and drug-resistance
strains of M. tuberculosis.2. Results and discussion
2.1. SAR analysis for anti-mycobacterial activity
Eighteen designed derivatives were ﬁrst measured for their
anti-tubercular activities against the multiplication ofFigure 1 Chemical structuresdrug-susceptible M. tuberculosis strain H37Rv with the
microplate alamar blue assay (MABA). RIF and INH were
used as the reference drugs. The structures of the 18
analogs and their anti-mycobacterial activities are shown in
Tables 1 and 2.
The SAR study was mainly focused on the substituents
at the 8-position of 2. Replacement of hydrogen at the 8-
position (R1) with methyl, ethyl, n-propyl, i-propyl, n-
butyl, n-pentyl, cyclopentyl, n-hexyl, or phenyl, respec-
tively, generated nine new analogs (6a-i). These compounds
showed moderate activity with MIC ranges between 1.0
and 32 mg/mL. Among these analogs, compounds 6f-h
afforded ideal anti-tubercular activities at an MIC value
of 2.0 mg/mL. Compound 6i, bearing phenyl on position 8,
exhibited the best activity with an MIC value of 1.0 mg/mL.
It indicated that introduction of a large substituent at the
8-position might be beneﬁcial for anti-mycobacterial
activity.
Next, SAR analysis was moved to the modiﬁcations at the
8-positions of 3. A methyl, ethyl, n-propyl, i-propyl, n-butyl,
n-pentyl, cyclopentyl, n-hexyl, and n-octyl was attached at the
8-position of dihydropalmatine, generating nine new analogs
(7a–i) which were prepared and tested. Compounds 7d, 7g and
7h showed moderate activity at an MIC of 4.0 mg/mL. Compound
7i bearing n-octyl at the 8-position exhibited ideal activity with an
MIC value of 2.0 mg/mL.2.2. Anti-resistant TB effect of the compound 6i
As compound 6i possessed excellent activity against drug-
susceptible M. tuberculosis strain H37Rv with an MIC of
1.0 mg/mL, it was further examined for its effect on the MDR
strains of M. tuberculosis. In this experiment, M. tuberculosis
strains 44, 83 and 699 were used; these strains were isolated
from patients with tuberculosis in China and were resistant to
both RIF and INH. As described in Table 3, RIF and INH
showed decreased activity against these drug-resistant strains
partially or completely with MIC ranging between 4 and
432 mg/mL. However, compound 6i afforded a reasonableof compounds 1, 2 and 3.
Table 2 SAR of 8-substituted dihydropalmatines against
M. tuberculosis strain H37Rv.
Compd. R2 MICa
7a CH3 128
7b C2H5 8
7c n-C3H7 8
7d i-C3H7 4
7e n-C4H9 8
7f n-C5H11 8
7g 4
7h n-C6H13 4
7i n-C8H17 2
RIFb 0.0625
INHc 0.0625
aMIC: minimum inhibitory concentration.
bRIF: Rifampin.
cINH: Isoniazid.
Table 3 In vitro anti-tubercular activities of compound 6i
against MDR strains of M. tuberculosisa (MIC: mg/mLb).
Compd. 44 83 699 H37Rv
6i 16 4 2 1
Table 1 SAR of 8-substituted berberines against M.
tuberculosis strain H37Rv.
Compd. R1 MICa
6a CH3 32
6b C2H5 16
6c n-C3H7 8
6d i-C3H7 16
6e n-C4H9 8
6f n-C5H11 2
6g 2
6h n-C6H13 2
6i Ph 1
RIFb 0.0625
INHc 0.0625
aMIC: minimum inhibitory concentration.
bRIF: Rifampin.
cINH: Isoniazid.
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16 mg/mL. The results revealed that compound 6i was active
for either drug-susceptible M. tuberculosis and those resistant
to RIF and INH, suggesting a novel mechanism of action
against TB.
RIF 4 4 4 32 0.0625
INH 432 432 32 0.0625
aMDR strains were isolated from patients with tuberculosis
in China.
bMIC: minimum inhibitory concentration.3. Conclusions
In conclusion, 18 new derivatives of dihydropseudoberber-
ine (2) and dihydropalmatine (3) with various substituents
at position 8 were synthesized and evaluated for their anti-
mycobacterial activities against M. tuberculosis H37Rv.
SAR analysis revealed that a large group at the 8-position
might be beneﬁcial for the anti-mycobacterial activity. This
might be an explanation as to why compounds 2 and 3 do
not show signiﬁcant activities against M. tuberculosis.
Among the test compounds, compound 6i exhibited sig-
niﬁcant activity against both drug-susceptible and MDR
strains of M. tuberculosis, suggesting a different mode of
action against TB in comparison to current drugs. Thus, it
has been selected as a lead compound for the development
of anti-TB agents.4. Experimental section
4.1. Chemistry
Melting point (mp) was obtained with CXM-300 melting point
apparatus and uncorrected. The 1H NMR spectra was
performed on a Varian Inova 400 MHz spectrometer (Varian,San Francisco, CA) and 13C NMR on a Bruker Avance III
400 spectrometer in DMSO-d6, with Me4Si as the internal
standard. ESI high-resolution mass spectra (HRMS) were
recorded on an Autospec UItima-TOF mass spectrometer
(Micromass UK Ltd., Manchester, UK). Flash chromatogra-
phy was performed on CombiﬂashRf 200 (Teledyne,
Nebraska, USA), particle size 0.038 mm.
Eighteen new 8-substituted dihydroberberine derivatives
were synthesized with 411,12 (synthesized in our laboratory)
or commercially available 5 as the starting materials, as
described in Scheme 1.
Grignard reagents were prepared via Magnesium turnings
(3.8 g) with the corresponding alkyl and phenyl iodides
(0.13 mol) in absolute ether (100 mL) at 0 1C. The synthesized
Grignard reagents were slowly added to the suspension of dry
4 or 5 (0.03 mol) in absolute ether (100 mL) under N2
protection at 0 1C13,14. After reﬂuxing for 2 h, saturated
NH4Cl solution (200 mL) was added to quench the reaction.
The aqueous phase was extracted with ethyl acetate
Yanxiang Wang et al.584(3 100 mL) and the combined organic layers were washed
with saturated brines (100 mL) and dried (Na2SO4). The
mixture was concentrated in vacuo to give 2 or 3. The residue
was acidiﬁed by 4 M HCl/EtOH (20 mL) at room tempera-
ture, and the solvent was removed by evaporation. The
products in series 6 or 7 were puriﬁed via ﬂash column
chromatography using methanol/dichloromethane as the gra-
dient eluent.4.1.1. 8-Methyl-7,8-dihydropseudoberberine choride (6a)
Yield: 78%; Pale white solid; mp: 141–143 1C; MS m/z 352
[MCl]þ; 1H NMR: d 7.22 (s, 1H), 6.75 (s, 1H), 6.65 (s, 1H),
6.58 (s, 1H), 5.98 (s, 2H), 5.88 (s, 1H), 4.46 (q, J¼6.4 Hz,
1H), 3.70 (s, 6H), 3.313.14 (m, 3H), 2.822.71 (m, 2H),
1.06 (d, J¼6.4 Hz, 3H); 13C NMR: d 147.8, 146.7, 146.3,
138.0, 128.6, 126.1, 125.3, 124.1, 109.4, 107.8, 107.0, 103.8,
100.9, 94.1, 58.0, 55.7, 55.5, 45.3, 29.6, 15.9, 8.8; IR (KBr):
2996.0, 2932.4, 2906.3, 1603.7, 1511.9, 1483.9, 1344.5,
1266.2, 1240.4, 1225.5, 1122.8, 1033.5, 865.9 cm1; HR
MS-ESI: m/z Calcd. C21H22NO4Cl 352.1549 [MCl]þ,
Found 352.1562.4.1.2. 8-Ethyl-7,8-dihydropseudoberberine choride (6b)
Yield: 75%; Pale white solid; mp: 162–164 1C (decomp.);
MS m/z 366 [MCl]þ; 1H NMR: d 7.76 (s, 1H), 7.18 (s, 1H),
6.97 (s, 1H), 6.91 (s, 1H), 6.25 (s, 2H), 5.17 (s, 1H),
4.854.79 (m, 1H), 4.514.45 (m, 1H), 4.134.05 (m,
2H), 3.78 (s, 3H), 3.77 (s, 3H), 3.163.09 (m, 2H),
2.121.95 (m, 2H), 0.79 (t, J¼7.2 Hz, 3H); 13C NMR: d
171.7, 154.0, 148.8, 148.2, 147.4, 135.7, 123.3, 119.7, 119.4,
110.2, 109.1, 108.8, 108.3, 103.1, 68.0, 55.8, 55.6, 50.1, 31.8,
27.6, 25.6, 8.6; IR (KBr): 3479.5, 3389.7, 2975.3, 1588.7,
1519.2, 1457.7, 1426.6, 1398.4, 1282.2, 1268.5, 1253.8,
1026.6 cm1; HR MS-ESI: m/z Calcd. C22H24NO4Cl
366.1705 [MCl]þ, Found 366.1708.4.1.3. 8-n-Propyl-7,8-dihydropseudoberberine choride (6c)
Yield: 73%; Yellow solid; mp: 159–161 1C (decomp.); MS m/z
380 [MCl]þ; 1H NMR: d 7.77 (s, 1H), 7.17 (s, 1H), 6.99Scheme 1 Synthesis pathway(s, 1H), 6.90 (s, 1H), 6.25 (s, 2H), 5.19 (s, 1H), 4.874.81 (m,
1H), 4.504.45 (m, 1H), 4.244.19 (m, 2H), 3.77 (s, 6H),
3.153.10 (m, 2H), 2.041.87 (m, 2H), 1.231.10 (m, 2H),
0.85 (t, J¼7.2 Hz, 3H); 13C NMR: d 171.7, 154.0, 148.8, 148.1,
147.3, 135.7, 123.9, 119.7, 119.4, 110.4, 109.2, 108.8, 108.3,
103.0, 67.3, 55.8, 55.6, 50.1, 36.3, 31.8, 25.6, 17.4, 13.5; IR
(KBr): 3641.5, 3362.2, 3275.9, 2964.3, 1592.4, 1517.0, 1425.8,
1400.1, 1343.0, 1283.9, 1256.1, 1141.2, 1105.5, 1021.9 cm1;
HR MS-ESI: m/z Calcd. C23H26NO4Cl 380.1862 [MCl]þ,
found 380.1878.4.1.4. 8-i-Propyl-7,8-dihydropseudoberberine choride (6d)
Yield: 79%; Orange solid; mp: 171174 1C (decomp.); MS
m/z 380 [MCl]þ; 1H NMR: d 7.79 (s, 1H), 7.18 (s, 1H), 7.02
(s, 1H), 6.83 (s, 1H), 6.25 (s, 2H), 5.11 (s, 1H), 4.874.81 (m,
1H), 4.484.42 (m, 1H), 4.254.14 (m, 2H), 3.78 (s, 3H), 3.77
(s, 3H), 3.153.05 (m, 2H), 1.08 (d, J¼6.4 Hz, 3H), 0.840.71
(m, 1H), 0.71 (t, J¼6.8 Hz, 3H); 13C NMR: d 172.1, 154.1,
148.9, 147.7, 147.4, 135.9, 121.4, 120.4, 119.7, 110.4, 110.2,
108.9, 108.3, 103.1, 72.4, 55.8, 55.6, 51.1, 33.5, 32.7, 25.6, 19.7,
16.8; IR (KBr): 3355.1, 2962.7, 1614.9, 1592.3, 1519.5, 1458.8,
1427.0, 1405.8, 1285.1, 1256.0, 1032.9, 873.2 cm1; HR MS-
ESI: m/z Calcd. C23H26NO4Cl 380.1862 [MCl]þ, Found
380.1864.4.1.5. 8-n-Butyl-7,8-dihydropseudoberberine choride (6e)
Yield: 78%; Light yellow solid; mp: 158161 1C (decomp.);
MS m/z 394 [MCl]þ; 1H NMR: d 7.76 (s, 1H), 7.17 (s, 1H),
6.98 (s, 1H), 6.90 (s, 1H), 6.25 (s, 2H), 5.19 (s, 1H),
4.864.80 (m, 1H), 4.504.45 (m, 1H), 4.244.08 (m,
2H), 3.78 (s, 3H), 3.77 (s, 3H), 3.153.09 (m, 2H),
2.081.91 (m, 2H), 1.281.15 (m, 4H), 0.81 (t, J¼7.2 Hz,
3H); 13C NMR: d 171.7, 154.0, 148.8, 148.1, 147.4, 135.7,
123.8, 119.7, 119.4, 110.3, 109.2, 108.8, 108.4, 103.1, 67.4,
55.8, 55.6, 50.1, 34.0, 31.9, 26.0, 25.6, 21.8, 13.7; IR (KBr):
3210.6, 2934.2, 2860.4, 1641.8, 1613.7, 1595.4, 1513.4,
1456.3, 1425.7, 1405.4, 1346.3, 1285.4, 1259.3, 1037.2,
870.8 cm1; HR MS-ESI: m/z Calcd. C24H28NO4Cl
394.2018 [MCl]þ, Found 394.2007.of the target compounds.
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Yield: 82%; Yellow solid; mp: 165–167 1C (decomp.); MS
m/z 408 [MCl]þ; 1H NMR: d 7.77 (s, 1H), 7.17 (s, 1H),
6.99 (s, 1H), 6.90 (s, 1H), 6.25 (s, 2H), 5.19 (s, 1H),
4.874.81 (m, 1H), 4.504.44 (m, 1H), 4.144.05 (m,
2H), 3.77 (s, 3H), 3.76 (s, 3H), 3.173.09 (m, 2H),
2.041.90 (m, 2H), 1.411.38 (m, 2H), 1.231.19 (m,
4H), 0.79 (t, J¼6.8 Hz, 3H); 13C NMR: d 171.7, 154.0,
148.8, 148.1, 147.4, 135.7, 123.8, 119.7, 119.4, 110.4, 109.2,
108.8, 108.4, 103.1, 67.4, 55.8, 55.6, 50.1, 34.2, 31.9, 30.8,
25.6, 23.6, 21.8, 13.8; IR (KBr): 3361.0, 2947.3, 1592.1,
1517.7, 1465.5, 1429.4, 1350.1, 1286.6, 1259.8, 1107.2,
1033.9, 877.5 cm1; HR MS-ESI: m/z Calcd. C25H30NO4Cl
408.2175 [MCl]þ, Found 408.2179.
4.1.7. 8-Cyclopentyl-7,8-dihydropseudoberberine choride (6g)
Yield: 77%; Yellow solid; mp: 223–226 1C (decomp.); MS
m/z 406 [MCl]þ; 1H NMR: d 7.84 (s, 1H), 7.58 (s, 1H),
7.07 (s, 1H), 6.25 (s, 1H), 6.16 (s, 1H), 6.11 (s, 2H),
4.874.81 (m, 1H), 4.714.55 (m, 1H), 4.504.35 (m,
2H), 3.45 (s, 3H), 3.43 (s, 3H), 3.033.01 (m, 2H),
2.282.07 (m, 3H), 1.911.71 (m, 6H); 13C NMR: d
158.2, 153.7, 151.3, 148.0, 145.8, 131.5, 131.3, 127.6,
120.3, 109.7, 107.1, 105.9, 104.6, 101.6, 56.8, 56.3, 55.8,
55.7, 32.8, 32.4, 31.7, 27.2, 27.1, 25.0, 24.9; IR (KBr):
3374.0, 2953.3, 2870.5, 1616.8, 1504.2, 1453.7, 1429.9,
1279.1, 1208.5, 1035.0 cm1; HR MS-ESI: m/z Calcd.
C25H28NO4Cl 406.2018 [MCl]þ, Found 406.2031.
4.1.8. 8-n-Hexyl-7,8-dihydropseudoberberine choride (6h)
Yield: 75%; Bright yellow solid; mp: 179–181 1C (decomp.);
MS m/z 422 [MCl]þ; 1H NMR: d 7.76 (s, 1H), 7.17 (s, 1H),
6.99 (s, 1H), 6.89 (s, 1H), 6.25 (s, 2H), 5.19 (s, 1H),
4.864.80 (m, 1H), 4.504.44 (m, 1H), 4.224.05 (m,
2H), 3.77 (s, 3H), 3.76 (s, 3H), 3.193.09 (m, 2H),
2.062.01 (m, 2H), 1.311.18 (m, 8H), 0.87 (t, J¼6.8 Hz,
3H); 13C NMR: d 171.7, 154.0, 148.8, 148.1, 147.4, 135.7,
123.9, 119.7, 119.4, 110.4, 109.2, 108.8, 108.4, 103.1, 67.4,
55.8, 55.6, 50.2, 34.3, 31.9, 31.0, 28.3, 25.6, 23.9, 22.0, 13.9;
IR (KBr): 3339.1, 2926.4, 22857.6, 1592.7, 1518.5, 1465.1,
1428.7, 1347.0, 1285.1, 1258.3, 1037.6 cm1; HR MS-ESI:
m/z Calcd C26H32NO4Cl 422.2331 [MCl]þ, Found
422.2331.
4.1.9. 8-Phenyl-7,8-dihydropseudoberberine choride (6i)
Yield: 71%; Orange solid; mp: 135–137 1C (decomp.); MS
m/z 412 [MCl]þ; 1H NMR: d 8.92 (s, 1H), 7.80 (s, 1H),
7.787.71 (m, 5H), 7.05 (s, 1H), 6.74 (t, J¼8.8 Hz, 1H),
6.57 (s, 1H), 6.18 (s, 2H), 4.32 (t, J¼6.4 Hz, 2H), 4.07 (s,
3H), 3.65 (s, 3H), 2.49 (t, J¼6.4 Hz, 2H); 13C NMR: d
157.0, 154.2, 152.0, 149.9, 147.7, 139.0, 136.5, 131.1, 130.8,
130.6, 129.5, 129.2, 128.9, 126.7, 122.6, 121.3, 118.9, 115.2,
108.0, 106.2, 105.7, 102.1, 56.8, 55.7, 51.8, 26.3; IR (KBr):
3387.6, 3028.2, 1612.0, 1566.7, 1500.9, 1466.1, 1427.4,
1267.4, 1036.9 cm1; HR MS-ESI: m/z Calcd. C26H22NO4Cl
412.1549 [MCl]þ, Found 412.1564.
4.1.10. 8-Methyl-7,8-dihydropalmatine choride (7a)
Yield: 78%; Pale white solid; mp: 148–150 1C; MS m/z 368
[MCl]þ; 1H NMR: d 8.88 (s, 1H), 8.18 (d, J¼10.2 Hz,
1H), 8.05 (d, J¼10.2 Hz, 1H), 7.64 (s, 1H), 7.11 (s, 1H), 4.76(t, J¼6.0 Hz, 2H), 4.05 (s, 3H), 3.94 (s, 3H), 3.92 (s, 3H), 3.86 (s,
3H), 3.15 (t, J¼6.0 Hz, 2H), 1.90 (s, 3H); 13C NMR: d 172.0,
159.1, 152.5, 151.3, 148.7, 145.6, 137.8, 132.3, 128.2, 125.1, 124.6,
119.5, 119.0, 110.6, 109.0, 61.4, 57.0, 55.8, 50.0, 25.9, 21.0, 20.4;
IR (KBr): 2948.3, 1758.8, 1733.8, 1607.4, 1521.0, 146.1, 1387.7,
1343.8, 1274.4, 1222.6, 1156.0, 1109.1, 864.4 cm1; HR MS-
ESI: m/z Calcd. C22H26NO4Cl 368.1705 [MCl]þ, Found
368.1706.
4.1.11. 8-Ethyl-7,8-dihydropalmatine choride (7b)
Yield: 81%; Bright yellow solid; mp: 172–174 1C (decomp.);
MS m/z 382 [MCl]þ; 1H NMR: d 7.66 (s, 1H), 7.12 (s, 1H),
7.17 (s, 2H), 5.39 (s, 1H), 4.96 (m, 1H), 4.54 (m, 1H),
4.254.13 (m, 2H), 3.92 (s, 3H), 3.91 (s, 3H), 3.86 (s, 3H),
3.84 (s, 3H), 3.183.10 (m, 2H), 2.082.04 (m, 2H), 0.77
(t, J¼7.6 Hz, 3H); 13C NMR: d 172.0, 155.8, 151.1, 148.0,
143.8, 133.2, 125.0, 122.4, 120.4, 118.1, 113.6, 112.5, 111.0,
62.3, 60.5, 56.4, 56.3, 56.0, 50.4, 31.6, 26.8, 25.1, 8.5; IR
(KBr): 3374.2, 2981.4, 1604.8, 1563.5, 1502.7, 1462.2,
1404.1, 1339.6, 1281.7, 1160.9, 997.0 cm1; HR MS-ESI:
m/z Calcd. C23H28NO4Cl 382.2018 [MCl]þ, Found 382.
2032.
4.1.12. 8-n-Propyl-7,8-dihydropalmatine choride (7c)
Yield: 83%; Brown solid; mp: 149–151 1C (decomp.); MS m/
z 396 [MCl]þ; 1H NMR: d 7.66 (s, 1H), 7.19 (s, 1H), 7.16
(s, 2H), 5.40 (s, 1H), 5.07 (m, 1H), 4.53 (m, 1H), 4.124.01
(m, 2H), 3.86 (s, 3H), 3.84 (s, 3H), 3.79 (s, 3H), 3.74 (s, 3H),
3.183.10 (m, 2H), 1.96 (s, 2H), 1.221.16 (m, 2H), 0.83
(t, J¼7.2 Hz, 3H); 13C NMR: d 172.0, 155.8, 151.1, 148.0,
143.8, 133.2, 125.5, 122.5, 120.3, 118.1, 113.5, 112.5, 111.0,
63.5, 60.5, 56.4, 56.3, 56.0, 50.5, 35.7, 31.6, 25.2, 17.3, 13.6;
IR (KBr): 3419.8, 2968.2, 1604.4, 1561.7, 1501.5, 1463.9,
1431.0, 1402.0, 1345.2, 1282.6, 1162.0, 1002.3 cm1; HR
MS-ESI: m/z Calcd. C24H30NO4Cl 396.2175 [MCl]þ,
Found 396.2184.
4.1.13. 8-i-Propyl-7,8-dihydropalmatine choride (7d)
Yield: 69%; Yellow solid; mp: 141–144 1C (decomp.); MS
m/z 396 [MCl]þ; 1H NMR: d 7.69 (s, 1H), 7.20 (s, 1H),
7.18 ;(s, 1H), 7.15 (s, 1H), 5.255.19 (m, 1H), 5.034.95
(m, 1H), 4.514.45 (m, 1H), 4.324.26 (m, 2H), 3.93 (s,
3H), 3.91 (s, 3H), 3.86 (s, 3H), 3.84 (s, 3H), 3.15 (t,
J¼7.6 Hz, 2H), 2.372.32 (m, 1H), 1.01 (d, J¼6.8 Hz,
3H), 0.91 (t, J¼6.8 Hz, 3H); 13C NMR: d 172.9, 155.9,
151.1, 148.1, 144.4, 133.4, 125.3, 122.6 121.1, 118.2, 113.9,
113.6, 112.7, 111.1, 69.2, 60.5, 56.4, 56.0, 52.3, 34.3, 32.4,
25.0, 19.2, 18.9; IR (KBr): 3366.0, 2973.9, 1604.8, 1561.1,
1499.9, 1464.6, 1400.4, 1290.5, 1161.3, 999.3 cm1; HR
MS-ESI: m/z Calcd. C24H30NO4Cl 396.2175 [MCl]þ,
Found 396.2184.
4.1.14. 8-n-Butyl-7,8-dihydropalmatine choride (7e)
Yield: 78%; Light yellow solid; mp: 166–168 1C (decomp.);
MS m/z 410 [MCl]þ; 1H NMR: d 7.66 (s, 1H), 7.19 (s, 1H),
7.17 (s, 2H), 5.39 (s, 1H), 5.014.95 (m, 1H), 4.554.50
(m, 1H), 4.304.20 (m, 2H), 3.92 (s, 3H), 3.91 (s, 3H), 3.85
(s, 3H), 3.84 (s, 3H), 3.213.03 (m, 2H), 2.011.96 (m, 2H),
1.261.13 (m, 4H), 0.79 (t, J¼7.2 Hz, 3H); 13C NMR: d
172.0, 155.8, 151.1, 148.0, 143.8, 133.2, 125.5, 122.5, 120.3,
118.1, 113.5, 112.5, 111.0, 63.6, 60.5, 56.4, 56.3, 56.0, 50.5,
Yanxiang Wang et al.58633.4, 31.6, 25.9, 25.2, 21.9, 13.7; IR (KBr): 3357.8, 2949.2,
1604.6, 1561.5, 1502.6, 1466.5, 1430.9, 1403.0, 1342.8, 1291.0,
1161.9, 1000.3 cm1; HR MS-ESI: m/z Calcd. C25H32NO4Cl
410.2331 [MCl]þ, Found 410.2340.4.1.15. 8-n-Pentyl-7,8-dihydropalmatine choride (7f)
Yield: 82%; Yellow solid; mp: 155–157 1C (decomp.); MS
m/z 424 [MCl]þ; 1H NMR: d 7.68 (s, 1H), 7.19 (s, 1H),
7.17 (s, 2H), 5.39 (s, 1H), 5.00 (m, 1H), 4.53 (m, 1H),
4.244.21 (m, 2H), 3.93 (s, 3H), 3.92 (s, 3H), 3.85 (s, 3H),
3.83 (s, 3H), 3.213.11 (m, 2H), 2.041.96 (m, 2H),
1.561.37 (m, 4H), 1.231.15 (m, 2H), 0.78 (t, J¼6.4 Hz,
3H); 13C NMR: d 172.0, 155.8, 151.1, 148.0, 143.9, 133.2,
125.5, 122.5, 120.4, 118.1, 113.5, 112.6, 111.0, 63.7, 60.5,
56.4, 56.0, 55.7, 50.6, 33.6, 31.6, 30.9, 25.2, 23.5, 21.8, 13.9;
IR (KBr): 2950.3, 2928.5, 1628.9, 1604.4, 1562.0, 1523.6,
1501.1, 1466.7, 1403.1, 1345.3, 1290.6, 1161.8, 1002.6 cm1;
HR MS-ESI: m/z Calcd. C26H34NO4Cl 424.2488 [MCl]þ,
Found 424.2498.4.1.16. 8-Cyclopentyl-7,8-dihydropalmatine choride (7g)
Yield: 77%; Yellow solid; mp: 163166 1C (decomp.); MS
m/z 424 [MCl]þ; 1H NMR: d 7.69 (s, 1H), 7.20 (s, 2H),
7.16 (s, 1H), 5.31 (d, J¼8.4 Hz, 1H), 5.00 (m, 1H), 4.45 (m,
1H), 4.31 (t, J¼7.2 Hz, 2H), 3.93 (s, 3H), 3.92 (s, 3H), 3.84
(s, 3H), 3.83 (s, 3H), 3.15 (t, J¼7.2 Hz, 2H), 2.382.32 (m,
1H), 1.661.35 (m, 8H); 13C NMR: d 172.6, 155.9, 151.1,
148.0, 143.9, 133.4, 126.2, 122.7, 121.2, 118.2, 113.4, 112.7,
111.1, 67.4, 60.6, 56.4, 56.0, 51.8, 45.0, 35.0, 32.0, 29.7, 28.8,
25.3, 24.0, 23.2; IR (KBr): 3391.5, 2948.6, 1604.9, 1559.7,
1496.7, 1464.8, 1397.3, 1341.0, 1281.5, 1228.3, 1162.4,
1002.4 cm1; HR MS-ESI: m/z Calcd. C26H32NO4Cl
424.2331 [MCl]þ, Found 424.2341.4.1.17. 8-n-Hexyl-7,8-dihydropalmatine choride (7h)
Yield: 75%; Bright yellow solid; mp: 154–157 1C (decomp.);
MS m/z 438 [MCl]þ; 1H NMR: d 7.66 (s, 1H), 7.19 (s, 1H),
7.16 (s, 2H), 5.39 (s, 1H), 5.98 (m, 1H), 4.52 (m, 1H),
4.304.20 (m, 2H), 3.92 (s, 3H), 3.91 (s, 3H), 3.85 (s, 3H),
3.84 (s, 3H), 3.183.09 (m, 2H), 2.001.97 (m, 2H), 1.281.10
(m, 8H), 0.79 (t, J¼6.4 Hz, 3H); 13C NMR: d 172.0, 155.8,
151.1, 148.0, 143.8, 133.2, 125.5, 122.5, 120.4, 118.1, 113.5,
112.5, 111.0, 63.6, 60.5, 56.4, 56.3, 56.0, 50.6, 33.6, 31.6, 31.0,
28.4, 25.2, 23.8, 22.0, 13.9; IR (KBr): 3384.7, 2934.2, 1605.5,
1562.5, 1524.2, 1501.5, 1465.3, 1431.7, 1344.6, 1286.1, 1226.9,
1163.5, 1004.3 cm1; HR MS-ESI: m/z Calcd. C27H36NO4Cl
438.2644 [MCl]þ, Found 438.2642.4.1.18. 8-n-Octyl-7,8-dihydropalmatine choride (7i)
Yield: 71%; Brown solid; mp: 135–137 1C (decomp.); MS
m/z 466 [MCl]þ; 1H NMR: d 7.66 (s, 1H), 7.19 (s, 1H),
7.16 (s, 2H), 5.39 (s, 1H), 5.97 (m, 1H), 4.51 (m, 1H),
4.284.21 (m, 2H), 3.92 (s, 3H), 3.91 (s, 3H), 3.85 (s, 3H),
3.84 (s, 3H), 3.183.07 (m, 2H), 2.051.93 (m, 2H),
1.261.10 (m, 12H), 0.80 (t, J¼6.4 Hz, 3H); 13C NMR: d
172.0, 155.8, 151.1, 148.0, 143.8, 133.2, 125.5, 122.5, 120.3,
118.1, 113.5, 112.5, 111.0, 63.6, 60.5, 56.4, 56.3, 56.0, 50.5,
33.6, 31.6, 31.1, 28.7, 28.6, 28.5, 25.2, 23.8, 22.0, 13.9; IR
(KBr): 2926.4, 2853.8, 1605.0, 1562.3, 1502.4, 1467.0,
1431.6, 1343.0, 1285.7, 1162.9, 1000.3 cm1; HR MS-ESI:m/z Calcd. C29H40NO4Cl 466.2957 [MCl]þ, Found
466.2961.4.2. Biological activity assay
RIF and INH were purchased from Sigma Company. All
8-substituted dihydropseudoberberine analogs were examined
for their activities against the multiplication of M. tuberculosis
strains with MABA at different concentrations. Two-fold
dilutions were performed in 100 mL of 7H9 media in 48-well
microplates, to which were added 100 mL of bacterial suspen-
sion per well. The amount of bacteria added to each well was
4 104 mg/mL. Plates were incubated at 37 1C. After incu-
bation, alamar blue solution was added and results were
recorded at 24 h post-reagent addition. Visual MIC value
was deﬁned as the lowest concentration of the drug that
prevented a color change.Acknowledgment
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